



DATE August 24 , 2020

FROM Christine Drabick, Bioresearch Monitoring Branch
Division of Inspections and Surveillance
Office of Compliance and Biologics Quality

THROUGH Dennis Cato, Branch Chief, Bioresearch Monitoring Branch

THROUGH Carrie Mampilly, Director, Division of Inspections and Surveillance

TO Matthew Klinker, Ph.D. Chair, BLA STN 125706/0
Kristin Baird, M.D. Clinical Reviewer
Adriane Fisher, M.P.H. RPM

SUBJECT Bioresearch Monitoring Final Discipline Review Memo

SPONSOR: Mesoblast Inc.

PRODUCT: Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Remestemcel-L,
Ryoncil) for Acute Graft versus Host Disease

BLA : STN: 125706/0

FINAL SUMMARY STATEMENT:

Bioresearch Monitoring (BIMO) inspections were issued for four clinical sites participating in the conduct of study protocols MSB-GVHD-001 (001) and MSB-GVHD-002 (002). The inspections did not reveal substantive problems impacting the data submitted in the application.

BACKGROUND:

Four BIMO clinical investigator inspection assignments were issued in support of this Biologics License Application. The clinical sites were selected based on subject enrollment, previous inspectional history, the data submitted in the BLA, and other factors.

Twenty United States sites consented at least one subject for Protocol 001 and Safety Follow-up Protocol 002. Fifty five subjects enrolled in Protocol 001 and 54 subjects were treated with remestemcel-L. Forty two subjects completed the study. A total of 40 subjects completed Protocol 001 alive and 32 subjects continued into Follow-up Protocol 002. The subjects enrolled at the four sites planned for inspection represent 40% of the subjects enrolled in Protocol 001 and 38% of the subjects continuing with follow-up in Protocol 002.

The inspection was conducted in accordance with FDA's Compliance Program (CP) 7348.811, Inspection Program for Clinical Investigators. Information submitted in the BLA was compared to source documents at the site. The inspection assignment included specific questions concerning the clinical study.

PROTOCOLS: The conduct of the following two protocols was evaluated:

A Single-arm, Prospective Study of Remestemcel-L, *Ex-vivo* Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients who Have Failed to Respond to Steroid Treatment for Acute GVHD (MSB-GVHD-001)

Safety Follow-up Through 180 Days of Treatment with Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD (MSB-GVHD-002)

BIMO INSPECTION SUMMARY:

Four BIMO inspection assignments were issued for this BLA. The inspections were classified as No Action Indicated (NAI).

Site ID	Location	FDA Form 483 Issued?	Inspection Classification*
301	Duke University Medical Center Durham, North Carolina	No	NAI
302	Memorial Sloan Kettering New York, New York	No	NAI
304	Ann and Robert H. Lurie Children's Hospital Chicago, Illinois	No	NAI
323	Pediatric Clinical Research Office Portland, Oregon	No	NAI

*NAI = No Action Indicated

SIGNIFICANT INSPECTIONAL FINDINGS:

No significant inspectional findings were observed.

SPONSOR ISSUES:

No sponsor issues were identified.

FINANCIAL DISCLOSURE:

The Clinical Investigator Compliance Program directs the FDA investigator to ask the clinical investigator if and when he/she disclosed information about his/her financial interests to the sponsor and/or interests of any sub-investigators, spouse(s) and dependent children, and if and when the information was updated. The information submitted to the BLA was verified for each of the inspected clinical sites.

ADMINISTRATIVE FOLLOW-UP:

Should you have any questions or comments about the contents of this memo or any aspect of Bioresearch Monitoring, please contact me at 240-402-8928.

Christine J. Drabick
Consumer Safety Officer

Distribution

Electronic Copy:

EDR BLA 125106/0
Matthew Kinker, Chair, STN 125106/0
Kristin Baird, Clinical Reviewer
Adriane Fisher, RPM
Carrie Mampilly, Director DIS
Dennis Cato, Branch Chief, BMB
CBER BIMO Notification
Bhanu Kannan for Chron File
ORA BIMOE Correspondence
ORA BIMOW Correspondence
Julian C. Hanson, FDA Investigator (OP ID 147588)
Jeanne Thai, FDA Investigator (OP ID 147587)
Omadevi Somai, FDA Investigator (OP ID 147586)
William Tonkins, FDA Investigator (OP ID 147585)

History:

Draft: Drabick: August 24, 2020